BMS/J&J (Janssen) Deal History & Licensing Activity
BMS/J&J (Janssen) is a large pharma headquartered in US. Over the past three years, BMS/J&J (Janssen) has been involved in 4 licensing and acquisition transactions, with a primary focus on Other (3 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Other
Focus Area
Oncology
BMS/J&J (Janssen) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving BMS/J&J (Janssen) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| 13-program collaboration | BMS | Other | Discovery | co development | May 30, 2026 |
BMS/J&J (Janssen) Pipeline Focus
Therapeutic areas and modalities where BMS/J&J (Janssen) is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
BMS/J&J (Janssen) Strategic Signals
Key indicators of BMS/J&J (Janssen)'s licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches BMS/J&J (Janssen)'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About BMS/J&J (Janssen) Licensing & Deal Activity
BMS/J&J (Janssen) is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, BMS/J&J (Janssen) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for BMS/J&J (Janssen) include Oncology (5 deals and trials). In terms of modality, BMS/J&J (Janssen) has shown particular interest in other, bispecific antibodies, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for BMS/J&J (Janssen) and 850+ other biopharma companies. Use our Solidus to benchmark your asset against BMS/J&J (Janssen)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.